Global Trends of Seroprevalence and Universal Screening Policy for Chagas Disease in Donors: a systematic review and meta-analysis

Kim, Jenny Yeon Hee; Ledien, Julia; Rodríguez-Monguí, Eliana; Dobson, Andy; Basáñez, María‐Gloria; Cucunubá, Zulma M.

doi:10.1101/2019.12.25.19015776

Cited by 1 publication

(1 citation statement)

References 16 publications

(16 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contexts where vectorial transmission has been interrupted, the model will need to integrate other transmission routes, which include mother-to-child transmission during pregnancy (congenital transmission) and through organ transplant or blood transfusion (transplant and transfusion transmission). While a substantial reduction in the transmission risk related to blood transfusion and organ transplantation has been observed, it remains the main transmission route in non-endemic countries [ 46 ]. Crucially, in the case of congenital transmission, even if the diagnosis is made during pregnancy, treatment should be delayed until after the delivery as it is contraindicated during pregnancy [ 47 ].…”

Section: Discussionmentioning

confidence: 99%

From serological surveys to disease burden: a modelling pipeline for Chagas disease

Ledien,

Cucunubá,

Parra-Henao

et al. 2023

Phil. Trans. R. Soc. B

Self Cite

View full text Add to dashboard Cite

In 2012, the World Health Organization (WHO) set the elimination of Chagas disease intradomiciliary vectorial transmission as a goal by 2020. After a decade, some progress has been made, but the new 2021–2030 WHO roadmap has set even more ambitious targets. Innovative and robust modelling methods are required to monitor progress towards these goals. We present a modelling pipeline using local seroprevalence data to obtain national disease burden estimates by disease stage. Firstly, local seroprevalence information is used to estimate spatio-temporal trends in the Force-of-Infection (FoI). FoI estimates are then used to predict such trends across larger and fine-scale geographical areas. Finally, predicted FoI values are used to estimate disease burden based on a disease progression model. Using Colombia as a case study, we estimated that the number of infected people would reach 506 000 (95% credible interval (CrI) = 395 000–648 000) in 2020 with a 1.0% (95%CrI = 0.8–1.3%) prevalence in the general population and 2400 (95%CrI = 1900–3400) deaths (approx. 0.5% of those infected). The interplay between a decrease in infection exposure (FoI and relative proportion of acute cases) was overcompensated by a large increase in population size and gradual population ageing, leading to an increase in the absolute number of Chagas disease cases over time. This article is part of the theme issue ‘Challenges and opportunities in the fight against neglected tropical diseases: a decade from the London Declaration on NTDs’.

show abstract

Section: Discussionmentioning

confidence: 99%